{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:14:56Z","timestamp":1766139296160,"version":"3.45.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Prilenia Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05393-4","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T07:15:10Z","timestamp":1763709310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sigma-2 Receptor Antagonism Enhances the Neuroprotective Effects of Pridopidine, a Sigma-1 Receptor Agonist, in Huntington\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Jing","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randal","family":"Hand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"4","key":"5393_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/17460441.2021.1838483","volume":"16","author":"T Maurice","year":"2021","unstructured":"Maurice T (2021) Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov 16(4):373\u2013389","journal-title":"Expert Opin Drug Discov"},{"issue":"91","key":"5393_CR2","first-page":"88508","volume":"6","author":"MP Niso","year":"2016","unstructured":"Niso MP (2016) ML; Berardi, F and Abate, C Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal s2 receptor binding and provide novel tools for the development of future s2 receptor PET radiotracers. Royal Society of Chemistry 6(91):88508\u201388518","journal-title":"Royal Society of Chemistry"},{"issue":"12","key":"5393_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/cmdc.201300291","volume":"8","author":"M Niso","year":"2013","unstructured":"Niso M et al (2013) Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity. ChemMedChem 8(12):2026\u20132035","journal-title":"ChemMedChem"},{"key":"5393_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/978-3-030-12457-1_28","volume":"1131","author":"B Delprat","year":"2020","unstructured":"Delprat B et al (2020) At the crossing of ER stress and MAMs: a key role of Sigma-1 receptor? Adv Exp Med Biol 1131:699\u2013718","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"5393_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131(3):596\u2013610","journal-title":"Cell"},{"issue":"2","key":"5393_CR6","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","volume":"18","author":"L Naia","year":"2021","unstructured":"Naia L et al (2021) The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models. Neurotherapeutics 18(2):1017\u20131038","journal-title":"Neurotherapeutics"},{"issue":"4","key":"5393_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","volume":"48","author":"ID Grachev","year":"2021","unstructured":"Grachev ID et al (2021) Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study. Eur J Nucl Med Mol Imaging 48(4):1103\u20131115","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"5393_CR8","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","volume":"232","author":"K Sahlholm","year":"2015","unstructured":"Sahlholm K et al (2015) Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology 232(18):3443\u20133453","journal-title":"Psychopharmacology"},{"key":"5393_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","volume":"129","author":"CR Eddings","year":"2019","unstructured":"Eddings CR et al (2019) Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis 129:118\u2013129","journal-title":"Neurobiol Dis"},{"issue":"5","key":"5393_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/ejn.15608","volume":"55","author":"HM Estevez-Silva","year":"2022","unstructured":"Estevez-Silva HM et al (2022) Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 55(5):1356\u20131372","journal-title":"Eur J Neurosci"},{"issue":"3","key":"5393_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1451-2","volume":"10","author":"A Ionescu","year":"2019","unstructured":"Ionescu A et al (2019) Targeting the Sigma-1 receptor via Pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis 10(3):210","journal-title":"Cell Death Dis"},{"issue":"5","key":"5393_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mds.27565","volume":"34","author":"TH Johnston","year":"2019","unstructured":"Johnston TH et al (2019) Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord 34(5):708\u2013716","journal-title":"Mov Disord"},{"issue":"2","key":"5393_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13311-018-00699-9","volume":"16","author":"V Francardo","year":"2019","unstructured":"Francardo V et al (2019) Pridopidine induces functional neurorestoration via the Sigma-1 receptor in a mouse model of Parkinson\u2019s disease. Neurotherapeutics 16(2):465\u2013479","journal-title":"Neurotherapeutics"},{"issue":"1","key":"5393_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0259-3","volume":"13","author":"R Kusko","year":"2018","unstructured":"Kusko R et al (2018) Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener 13(1):25","journal-title":"Mol Neurodegener"},{"issue":"2","key":"5393_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.15366","volume":"158","author":"M Shenkman","year":"2021","unstructured":"Shenkman M et al (2021) Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. J Neurochem 158(2):467\u2013481","journal-title":"J Neurochem"},{"key":"5393_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","volume":"124","author":"D Ryskamp","year":"2019","unstructured":"Ryskamp D et al (2019) Pridopidine stabilizes mushroom spines in mouse models of Alzheimer\u2019s disease by acting on the sigma-1 receptor. Neurobiol Dis 124:489\u2013504","journal-title":"Neurobiol Dis"},{"key":"5393_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105857","volume":"173","author":"S Lenoir","year":"2022","unstructured":"Lenoir S et al (2022) Pridopidine rescues BDNF\/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiol Dis 173:105857","journal-title":"Neurobiol Dis"},{"issue":"1","key":"5393_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01077-w","volume":"11","author":"M Geva","year":"2021","unstructured":"Geva M et al (2021) Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. Sci Rep 11(1):21975","journal-title":"Sci Rep"},{"issue":"Pt A","key":"5393_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"D Ryskamp","year":"2017","unstructured":"Ryskamp D et al (2017) The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis 97(Pt A):46\u201359","journal-title":"Neurobiol Dis"},{"issue":"18","key":"5393_CR20","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"M Geva","year":"2016","unstructured":"Geva M et al (2016) Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet 25(18):3975\u20133987","journal-title":"Hum Mol Genet"},{"issue":"27","key":"5393_CR21","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1073\/pnas.1705154114","volume":"114","author":"A Alon","year":"2017","unstructured":"Alon A et al (2017) Identification of the gene that codes for the sigma(2) receptor. Proc Natl Acad Sci U S A 114(27):7160\u20137165","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5393_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","volume":"37","author":"DS Malar","year":"2023","unstructured":"Malar DS et al (2023) Targeting Sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs 37(5):399\u2013440","journal-title":"CNS Drugs"},{"issue":"1","key":"5393_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35430-3","volume":"8","author":"A Riad","year":"2018","unstructured":"Riad A et al (2018) Sigma-2 receptor\/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Sci Rep 8(1):16845","journal-title":"Sci Rep"},{"issue":"10","key":"5393_CR24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/cmdc.201200246","volume":"7","author":"C Abate","year":"2012","unstructured":"Abate C et al (2012) 2-aminopyridine derivatives as potential sigma(2) receptor antagonists. ChemMedChem 7(10):1847\u20131857","journal-title":"ChemMedChem"},{"key":"5393_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110078","volume":"86","author":"H Shen","year":"2021","unstructured":"Shen H et al (2021) TMEM97 ablation aggravates oxidant-induced retinal degeneration. Cell Signal 86:110078","journal-title":"Cell Signal"},{"issue":"19","key":"5393_CR26","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1021\/acschemneuro.2c00274","volume":"13","author":"J Jin","year":"2022","unstructured":"Jin J et al (2022) Neuroprotective effects of sigma(2)R\/TMEM97 receptor modulators in the neuronal model of Huntington\u2019s disease. ACS Chem Neurosci 13(19):2852\u20132862","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"5393_CR27","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jnr.24782","volume":"99","author":"CS Limegrover","year":"2021","unstructured":"Limegrover CS et al (2021) Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson\u2019s patient brain-derived alpha-synuclein. J Neurosci Res 99(4):1161\u20131176","journal-title":"J Neurosci Res"},{"key":"5393_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076251","author":"BN Lizama","year":"2023","unstructured":"Lizama BN et al (2023) Sigma-2 receptors-from basic biology to therapeutic target: a focus on age-related degenerative diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24076251","journal-title":"Int J Mol Sci"},{"issue":"23","key":"5393_CR29","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1021\/acs.jmedchem.3c01441","volume":"66","author":"M Korff","year":"2023","unstructured":"Korff M et al (2023) Synthesis and biological evaluation of enantiomerically pure (R)- and (S)-[18F]OF-NB1 for imaging the GluN2B subunit-containing NMDA receptors. J Med Chem 66(23):16018\u201316031","journal-title":"J Med Chem"},{"issue":"12","key":"5393_CR30","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1021\/acs.jmedchem.0c02265","volume":"64","author":"AN Fallica","year":"2021","unstructured":"Fallica AN et al (2021) Recent advances in the development of sigma receptor ligands as cytotoxic agents: a medicinal chemistry perspective. J Med Chem 64(12):7926\u20137962","journal-title":"J Med Chem"},{"issue":"47","key":"5393_CR31","doi-asserted-by":"publisher","first-page":"19238","DOI":"10.1074\/jbc.M117.782300","volume":"292","author":"N Arbez","year":"2017","unstructured":"Arbez N et al (2017) Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity. J Biol Chem 292(47):19238\u201319249","journal-title":"J Biol Chem"},{"issue":"17","key":"5393_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104671","volume":"39","author":"RN Hegde","year":"2020","unstructured":"Hegde RN et al (2020) TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington\u2019s disease models. EMBO J 39(17):e104671","journal-title":"EMBO J"},{"issue":"8","key":"5393_CR33","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1021\/acs.jproteome.6b00991","volume":"16","author":"T Ratovitski","year":"2017","unstructured":"Ratovitski T et al (2017) Post-translational modifications (PTMs), identified on endogenous Huntingtin, cluster within proteolytic domains between HEAT repeats. J Proteome Res 16(8):2692\u20132708","journal-title":"J Proteome Res"},{"issue":"2","key":"5393_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088284","volume":"9","author":"EE Watkin","year":"2014","unstructured":"Watkin EE et al (2014) Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity. PLoS One 9(2):e88284","journal-title":"PLoS One"},{"key":"5393_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2022.935438","volume":"4","author":"S Wang","year":"2022","unstructured":"Wang S et al (2022) Fluorescently labeled nuclear morphology is highly informative of neurotoxicity. Front Toxicol 4:935438","journal-title":"Front Toxicol"},{"issue":"1","key":"5393_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03704-2","volume":"5","author":"R Rose","year":"2022","unstructured":"Rose R et al (2022) Chromatin compaction precedes apoptosis in developing neurons. Commun Biol 5(1):797","journal-title":"Commun Biol"},{"issue":"2","key":"5393_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jneumeth.2006.10.026","volume":"161","author":"SM Nguyen","year":"2007","unstructured":"Nguyen SM, Lieven CJ, Levin LA (2007) Simultaneous labeling of projecting neurons and apoptotic state. J Neurosci Methods 161(2):281\u2013284","journal-title":"J Neurosci Methods"},{"issue":"8","key":"5393_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/alz.12302","volume":"17","author":"NJ Izzo","year":"2021","unstructured":"Izzo NJ et al (2021) Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification. Alzheimers Dement 17(8):1365\u20131382","journal-title":"Alzheimers Dement"},{"issue":"4","key":"5393_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/bjc.2011.602","volume":"106","author":"C Zeng","year":"2012","unstructured":"Zeng C et al (2012) Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer 106(4):693\u2013701","journal-title":"Br J Cancer"},{"issue":"1","key":"5393_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/15548627.2022.2063003","volume":"19","author":"SM Wang","year":"2023","unstructured":"Wang SM et al (2023) Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1\/sigma-1 receptor chaperone by pridopidine. Autophagy 19(1):126\u2013151","journal-title":"Autophagy"},{"key":"5393_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050659","author":"SR Steinfield","year":"2025","unstructured":"Steinfield SR et al (2025) A review of the clinical progress of CT1812, a novel sigma-2 receptor antagonist for the treatment of Alzheimer\u2019s disease. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18050659","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"5393_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1089\/aid.1994.10.907","volume":"10","author":"VA Johnson","year":"1994","unstructured":"Johnson VA (1994) Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses 10(8):907\u2013912","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"23","key":"5393_CR43","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R et al (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022\u201338043","journal-title":"Oncotarget"},{"issue":"7899","key":"5393_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P et al (2022) Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603(7899):166\u2013173","journal-title":"Nature"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05393-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:03:19Z","timestamp":1763715799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05393-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5393"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05393-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"type":"print","value":"0893-7648"},{"type":"electronic","value":"1559-1182"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"121"}}